{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doravirine&page=2",
    "query": {
      "intervention": "Doravirine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doravirine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T09:23:17.107Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06719570",
      "title": "A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MK-8591A",
          "type": "DRUG"
        },
        {
          "name": "Islatravir",
          "type": "DRUG"
        },
        {
          "name": "Doravine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2024-01-23",
      "completion_date": "2024-03-15",
      "has_results": false,
      "last_update_posted_date": "2024-12-06",
      "last_synced_at": "2026-09-28T09:23:17.107Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06719570"
    },
    {
      "nct_id": "NCT04900974",
      "title": "Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections",
        "Pregnancy Related"
      ],
      "interventions": [
        {
          "name": "Doravirine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 7,
      "start_date": "2022-06-09",
      "completion_date": "2025-04-08",
      "has_results": true,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-09-28T09:23:17.107Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04900974"
    },
    {
      "nct_id": "NCT04518228",
      "title": "Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV",
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Bictegravir (BIC)",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir alafenamide (TAF)",
          "type": "DRUG"
        },
        {
          "name": "Long-acting injectable formulation of cabotegravir (CAB LA)",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir/ritonavir (ATV/r)",
          "type": "DRUG"
        },
        {
          "name": "Darunavir/ritonavir (DRV/r)",
          "type": "DRUG"
        },
        {
          "name": "Lopinavir/ritonavir (LPV/r)",
          "type": "DRUG"
        },
        {
          "name": "Cobicistat",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "First-Line TB Treatment",
          "type": "DRUG"
        },
        {
          "name": "Second-Line TB Treatment",
          "type": "DRUG"
        },
        {
          "name": "Doravirine (DOR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 205,
      "start_date": "2021-09-01",
      "completion_date": "2025-07-10",
      "has_results": true,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-28T09:23:17.107Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04518228"
    },
    {
      "nct_id": "NCT03886701",
      "title": "Doravirine, Rifapentine and Isoniazid Interaction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Latent Tuberculosis",
        "Human Immunodeficiency Virus",
        "Rifamycins Causing Adverse Effects in Therapeutic Use",
        "Drug Interaction Potentiation"
      ],
      "interventions": [
        {
          "name": "Doravirine (DOR)",
          "type": "DRUG"
        },
        {
          "name": "Rifapentine (RPT)",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid (INH)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walter K. Kraft",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 11,
      "start_date": "2019-04-22",
      "completion_date": "2019-05-20",
      "has_results": true,
      "last_update_posted_date": "2020-03-27",
      "last_synced_at": "2026-09-28T09:23:17.107Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03886701"
    },
    {
      "nct_id": "NCT04233216",
      "title": "Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "ISL",
          "type": "DRUG"
        },
        {
          "name": "DOR",
          "type": "DRUG"
        },
        {
          "name": "DOR/ISL",
          "type": "DRUG"
        },
        {
          "name": "Placebo to ISL",
          "type": "DRUG"
        },
        {
          "name": "Placebo to DOR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 35,
      "start_date": "2020-03-18",
      "completion_date": "2023-11-01",
      "has_results": true,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-09-28T09:23:17.107Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04233216"
    },
    {
      "nct_id": "NCT04538040",
      "title": "Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Quest Clinical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "45 Years and older · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2019-12-19",
      "completion_date": "2021-11-11",
      "has_results": true,
      "last_update_posted_date": "2024-03-05",
      "last_synced_at": "2026-09-28T09:23:17.107Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04538040"
    },
    {
      "nct_id": "NCT06630299",
      "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-Infection"
      ],
      "interventions": [
        {
          "name": "ISL/LEN",
          "type": "DRUG"
        },
        {
          "name": "Antiretroviral Combinations",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2024-10-08",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-09-28T09:23:17.107Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06630299"
    },
    {
      "nct_id": "NCT04636437",
      "title": "Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Doravirine 100 Mg",
          "type": "DRUG"
        },
        {
          "name": "Integrase strand transfer inhibitors",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir alafenamide/emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "tenofovir disproxil fumarate/emtricitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2021-07-27",
      "completion_date": "2024-10-18",
      "has_results": true,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-09-28T09:23:17.107Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04636437"
    },
    {
      "nct_id": "NCT04375800",
      "title": "Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Immunodeficiency Virus (HIV) Infection"
      ],
      "interventions": [
        {
          "name": "Doravirine",
          "type": "DRUG"
        },
        {
          "name": "2 NRTIs",
          "type": "DRUG"
        },
        {
          "name": "DOR/3TC/TDF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "4 Weeks to 11 Years"
      },
      "enrollment_count": 84,
      "start_date": "2021-02-03",
      "completion_date": "2034-04-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-09-28T09:23:17.107Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04375800"
    },
    {
      "nct_id": "NCT04295772",
      "title": "Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "DOR/ISL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 42,
      "start_date": "2020-11-26",
      "completion_date": "2023-01-25",
      "has_results": true,
      "last_update_posted_date": "2024-01-31",
      "last_synced_at": "2026-09-28T09:23:17.107Z",
      "location_count": 4,
      "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04295772"
    }
  ]
}